The discovery, over a decade ago, of endothelial progenitor cells that are able to participate in neovascularization of adult tissue has been greeted enthusiastically because of the potential for new cell-based therapies for therapeutic angiogenesis. Since that time, an ever-growing list of candidate cells has been proposed for cardiovascular regeneration. However, to date, pre-clinical and clinical studies evaluating the therapeutic potential of various cell therapies have reported conflicting results, generating controversy. Key issues within the field of cell therapy research include a lack of uniform cellular definitions, as well as inadequate functional characterization of the role of putative stem/progenitor cells in angiogenesis. Given the mixed results of initial clinical studies, there is now a scientific imperative to understand better the vascular biology of candidate cells in order to better translate cell therapy to the bedside. This review will provide a translationally relevant overview of the biology of candidate stem/progenitor cells for therapeutic angiogenesis.
Introduction
Faced with an ever-increasing burden of degenerative diseases, modern medicine is confronted with the need to provide therapies that not only mitigate the symptoms of these diseases, but may also facilitate regeneration of organ function. Given their role in development, and in maintaining and repairing senescent or diseased adult tissues, stem and progenitor cells represent an exciting alternative modality for regenerative cardiovascular medicine. Currently, a significant number of patients are ineligible for traditional methods of re-vascularization, such as angioplasty or coronary artery bypass grafting. 1 Early strategies to improve revascularization in such patients focused on modulation of proangiogenic growth factors with limited success. 2 With the number of 'no option' patients expected to increase, the need to serve these patients better represents a major unmet clinical need within cardiovascular medicine.
Over a decade ago, Asahara et al. described putative endothelial progenitor cells (EPCs) that were thought to mobilize from the bone marrow to participate in neovascularization at sites of ischemia. 3 The discovery was greeted enthusiastically because of the potential for new cell-based therapies for therapeutic angiogenesis. Early pre-clinical studies were undertaken in various small and large animal models, evaluating the therapeutic potential of bone marrow-derived cells (BMCs) thought to contain EPCs. These studies reported that BMCs functionally contributed to vascular regeneration in a number of different contexts, including graft re-endothelialization, wound healing, hindlimb ischemia and myocardial infarction (MI). 4 In addition to EPCs and BMCs, an ever-increasing number of other candidate cell therapies have also been proposed, including mesenchymal stem cells, embryonic stem cells, cardiac stem cells. 5 Studies of these cells have reported their ability to potentially regenerate damaged myocardium through differentiation into cardiomyocytes as well as through the promotion of neovascularization.
The progression of cell therapy from bench to attempted translation to bedside was rapid, with initial clinical studies using BMCs beginning in 1999, 6 despite ongoing debate regarding the nature of the cells used and their precise role in vascular regeneration. 7 Initial pilot studies reported that administration of these cells in the context of recent MI appears to be safe and associated with improved blood flow and left ventricular function. [8] [9] [10] [11] [12] However, recent larger randomized clinical trials evaluating the efficacy of different BMC preparations have yielded inconsistent data, with some studies reporting small but significant improvement in cardiac function 13 and others reporting largely neutral results. 14, 15 These conflicting clinical data have re-ignited interest in the unresolved questions regarding the biology of candidate cell therapies and how best to optimize these cells for therapeutic angiogenesis. There is still an incomplete understanding of the cellular processes involved in neovascularization, or the cell type(s) that are most suitable for therapeutic use. Additionally, there is still a lack of consensus as to the definition of an EPC and the methods used to isolate one. 16 Hence, it is now widely appreciated that discrepancies between clinical studies have largely arisen as the result of using ill-defined, heterogeneous bone marrow cell preparations.
Therefore, having moved quickly from the bench to the beside, it behooves for us to return to the bench in order to elucidate the biology of candidate cells so that the great hope of cellular therapeutic neovascularization can be fully realized. This review will provide a translationally relevant overview of the biology of candidate stem/progenitor cells for therapeutic angiogenesis.
The stem/progenitor cell hierarchy Stem cells are characterized by their capacity for self-renewal and their ability to differentiate into various functional cell types ( Figure 1 ). Totipotency refers to the ability of a cell to form cells of all lineages including the extraembryonic tissue. In mammals, the only cells with this capacity are the zygote and early blastomeres. 17 Pluripotency is the term applied to cells that have the ability to differentiate into all the cell types of the body, except the extraembryonic tissue (placenta). These cells include embryonic stem cells (ESCs), which were isolated from humans only 10 years ago, 18 and the recently discovered induced pluripotent stem (iPS) cells. 19, 20 Both these types of pluripotent stem cells have recently been investigated for their potential use in cardiovascular regeneration. 21, 22 Multipotent stem cells are those that have the ability to differentiate into a limited number of different cell types. These are sometimes referred to as 'adult stem cells' as they are more specialized or committed to a lineage, having the ability to differentiate into all the cells of that lineage. 17 ESCs are, as their name suggests, isolated from the inner cell mass of an embryo, whereas adult stem cells are isolated from postnatal tissue such as bone marrow, adipose tissue or umbilical cord blood. 23 The biggest difference between adult stem cells and ESCs are their respective development potentials. ESCs are pluripotent and self-renewing, whereas adult stem cells have lower self-renewal capacity. An example of a multipotent adult stem cell is the hematopoietic stem cell (HSC) as it can differentiate into all the cells of the blood. 24 Other stem or progenitor cells are unipotent, that is, they have the capacity to form only one kind of cell. An example of a unipotent stem cell is the spermatogonial stem cell, which can only form sperm.
Some confusion exists regarding the terminology of adult stem cells versus progenitor cells and, often, they are used interchangeably. However, these two cell types can be distinguished by their capacity for self-renewal and their potentiality. 25 That is, stem cells have an increased capacity for self-renewal and are often multipotent, whereas progenitors have a limited capacity for self-renewal and are often monopotent. For example, HSCs give rise to progeny that progressively lose self-renewal capacity and become restricted to one lineage, such as the myeloid progenitor that gives rise to white blood cells. 26 Scientists have investigated a variety of pluripotent stem cells, and multipotent stem and progenitor cells that can mediate cardiovascular regeneration via neovascularization and/or cardiomyocyte replacement. For the sake of concision, this review will focus on those cells that have shown involvement in therapeutic neovascularization.
Therapeutic neovascularization: what cell properties are required?
The creation of new postnatal blood vessels was, until a decade ago, thought only to occur by the mechanism of angiogenesis. Namely, the branching or elongation of existent vessels, by the migration and proliferation of endothelial cells (ECs). 27 It was hypothesized that, in the same way that hematopoietic recovery and ongoing replenishment of blood cells is provided by circulating hematopoietic stem cells (HSCs), there may be similar stem or progenitor cells that provide the same kind of support in endothelial regeneration, and participate in vessel formation. 28, 29 If such a cell existed and were capable of participation in therapeutic angiogenesis, what inherent properties would be required? It would need the ability to (i) be mobilized from its location (e.g. bone marrow) in response to an external stimulus, such as tissue ischemia, and (ii) successfully home to the site of ischemia. 30 Having arrived at the site of ischemia, the cell would (iii) participate in neovessel formation. 31 These three processes are discussed below.
Mobilization
Stem cell niches are specific sites where stem/progenitor cells reside in both undifferentiated and quiescent, or differentiated states. 32 Recruitment of these cells from the stem cell niche into the circulation is tightly regulated and occurs as a result of various stimuli. Perhaps the most potent stimulus for the recruitment of bone marrow derived progenitors, to any tissue, is hypoxia. 33 The response of cells adjacent to sites of ischemia is to secrete growth factors, chemokines and matrix metalloproteinases, the end result of which is cellular recruitment. 34 This process was found to be under the control of the hypoxia-inducible transcription factor (HIF-1), which senses low oxygen levels and drives the transcription of a number of different proangiogenic peptides, including stromal cell-derived factor 1 (SDF-1) and its receptor CXCR4. 35 High constitutive expression of SDF-1 in the bone marrow (normally a hypoxic environment 36 ) allows the retention of stem cells despite increased shear stress. 37 Following an ischemic event, stem cells home to the affected tissue on account of the SDF-1 signal. Other important HIF-regulated factors include vascular endothelial growth factor (VEGF) and erythropoietin (EPO), which have both been reported to mediate mobilization of EPCs. 38, 39 The role of these and other factors in stem cell mobilization are reviewed elsewhere. 30 Homing and transmigration The term 'homing' refers to the ability of a circulating cell to travel to a target tissue (such as the heart after MI) or to the bone marrow. For a prospective pro-angiogenic stem/progenitor cell to home to its destination, it will need to interact with the microvasculature, transmigrate through the endothelial layer and invade the target tissue. This homing capacity is needed regardless of whether the cell is endogenously mobilized or artificially administered to the target tissue. The adhesion molecules that are typically associated with rolling adhesion and arrest of circulating leukocytes have also been found to mediate stem cell homing; namely, P-and E-selectin, intercellular adhesion moleule-1 (ICAM-1), and vascular endothelial cell adhesion molecule-1 (VCAM-1). 40, 41 For mobilized cells to participate in tissue repair, they need to transmigrate the endothelium and invade the injured tissue. As such, expression of matrix degrading enzymes such as the matrix metalloproteinases MMP-2 and MMP-9 42 and cathepsin L 43 are essential for successful homing.
Neovascularization
The generic term neovascularization refers to the formation of new postnatal vessels, typically in proliferating, injured, or ischemic tissue. Therefore, this term Figure 1 Illustration of the stem cell hierarchy. Totipotency refers to the ability of a stem cell to form all cell types including extraembryonic tissue. Pluripotent stem cells are capable of unlimited self-renewal and can differentiate into any adult cell type (e.g. embryonic stem cells (ESCs) and induced pluripotent cells (iPS) cells). Multipotent stem cells have the ability to differentiate into a limited number of different cell types (e.g. hematopoietic stem cells (HSCs)). These multipotent stem cells can give rise to progenitor cells which can be multipotent (e.g. cardiac progenitor cells can differentiate into endothelial cells, smooth muscle cells or cardiomyocytes) or monopotent, giving rise to only one cell type (e.g. endothelial progenitor cells (EPCs)).
potentially includes all elements of the classic schema of new vessel formation: angiogenesis, arteriogenesis, and possibly adult vasculogenesis defined elsewhere. 44 As such, whether by endogenous mobilization and homing or artificial introduction to the site of ischemia, the candidate cell will first need to survive the hypoxic, indeed cytotoxic, environment. 45 Subsequently, the cell will need to participate in or facilitate the processes of vessel formation mentioned above. The precise contribution of various stem/progenitor cells to vessel formation is still under intense investigation.
Candidate cells for vascular regeneration
Currently there exist a growing number of cell types with differing properties and origins with the potential for therapeutic use in neovascularization ( Table 1 ). We will now go on to discuss the identity, origins and properties of a number of candidates, with a particular focus on the EPC.
Adult stem/progenitor cells

Endothelial progenitor cells (EPCs)
What is an EPC? In 1997, the long-held paradigm that angiogenesis was carried out by resident ECs was shifted by the findings of Asahara et al., who were the first to describe putative endothelial progenitor cells (EPCs). 3 These cells were described as immature cells expressing CD34 and vascular endothelial growth factor receptor (VEGFR-2, also known as kinase domain insert receptor, KDR) that could mobilize from the bone marrow to sites of ischemia and participate in and/or facilitate new vessel formation. However, the precise definition and role of EPCs in neovascularization remain debated issues. Indeed, a lack of understanding regarding the identity and biological role of putative EPCs has hampered attempts to successfully translate cell therapy to the bedside.
Defining EPCs by flow cytometry relies on immunolabeling cells for the presence of certain extracellular markers. Asahara et al. originally isolated CD34 positive cells from peripheral blood that went on to develop an EC-like profile after culture for 7 days on fibronectin, with expression of various endothelial markers (CD31, KDR, Tie-2 and endothelial nitric oxide synthase (eNOS)). 3 CD34, a hematopoietic stem cell marker, is used to identify both hematopoietic and endothelial progenitors, which are thought to derive from a putative common ancestor, termed the hemangioblast. 46 Accordingly, another, more primitive marker, thought to identify more immature progenitors, AC133 or CD133, has also been used to identify putative EPCs. 47, 48 It has been demonstrated that CD133 positive cells retain the ability to differentiate into ECs; however, the function of this 120-kD cholesterol binding protein remains unknown. 49 Yet, unlike CD34, CD133 is not expressed on mature ECs, it is lost somewhere in the differentiation process, hence its selection in trying to distinguish EPCs from circulating mature ECs that may have sloughed from the vessel wall. KDR, which mediates VEGF signaling, is the prototypical endothelial antigen, thus the trilogy of CD34, CD133 and KDR has long been the putative definition for an EPC. 3, 28, 46, 48 However, recent studies seeking to address the confusion regarding the identity and origin of EPCs suggest that EPCs do not derive from cells expressing CD133. 50, 51 Significant difficulties arise in the phenotypic characterization of EPCs, and indeed ECs, as there is no single marker, or simple combination of markers that are specific for either cell type. Indeed, there is significant overlap in the antigens expressed by various cell types. Hematopoietic stem cell populations express both CD34 and CD133, as well as a number of other traditional endothelial markers including KDR and Tie-2. 52, 53 Numerous studies have also shown co-expression of a raft of endothelial antigens, as well as the uptake of Dil-labeled acetylated low-density lipoprotein (AcLDL) and the binding of ulex lectin by circulating monocyte/ 54, 55 A recent study of various bone marrow-derived cells demonstrated specific expression of eNOS by putative EPCs, suggesting this may be a means by which to identify endothelial progenitors. 56 However, eNOS expression has also been shown in a variety of cells including CD14 and CD45 positive cells as well as embryonic stem cells. 55, 57 Early versus late EPCs In addition to flow cytometric definitions of EPCs, culture-based techniques have also been used to characterize EPCs. In general, these techniques involve the culture of isolated peripheral bloodderived mononuclear cells (PBMNCs) in endothelial growth medium. Interestingly, the culture of mononuclear cells on collagen or fibronectincoated plastic in endothelial cell growth medium reveals two distinct putative EPC populations, which have been classified primarily according to the time at which they appear in culture: early EPCs and late outgrowth endothelial cells (OECs) ( Table 2) . 58 Early EPCs, which appear in culture after 4-7 days, are similar to those originally described by Asahara et al., 3 while OECs appear much later in culture, after 14-21 days. 59 These two different populations of cells are also phenotypically and morphologically distinct. Bone marrow is widely appreciated as an abundant source of EPCs and other progenitors. However, a variety of tissues including the spleen, adipose tissue, the vascular wall and the adventitia have been implicated as sources of EPCs. 60, 62, 63 A recent study also identified high levels of mobilized tissue-residing progenitor in the intestine and the liver. 64 Using a parabiosis animal model, Aicher and colleagues were able to demonstrate the material contribution of these tissue-bound progenitors to vascular structures accompanied by enhanced neovascularization and perfusion in ischemic hindlimbs.
The role of EPCs in vascular regeneration
The rapid replenishment of damaged or denuded endothelium is an important factor in maintaining vessel integrity and preventing intimal hyperplasia. The specific role of EPCs in vascular repair remains debated. However, mounting evidence suggests EPCs significantly enhance re-endothelialization in injured or diseased arteries. In various animal models, regenerating cells in arterial and venous grafts were found to derive from recipient circulating EPCs and not donor-derived ECs. 65, 66 Indeed, in an early study by Shi et al., an artificial graft implanted in a dog with prior bone marrow transplantation was exclusively endothelialized by donor-derived bone marrow cells. 28 Importantly, EPCs have been shown to contribute to the endothelial monolayer and improve endothelial function. 62 In models of arterial injury, both administration of isolated EPCs and mobilization of endogenous EPCs enhanced the restoration of the endothelial monolayer, and reduced neointimal hyperplasia. [67] [68] [69] Although the extent of graft endothelialization is higher in animals compared to humans, 70 even in the absence of mechanical arterial injury, EPCs from transplanted granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood were found to constitute up to 25% of the aortic endothelium in a human. 71 In addition to participating in maintenance of the endothelium, EPCs have been repeatedly found at the foci of neovascularization. In studies assessing putative EPCs in pigs, transendocardial catheter-based application of autologous cells resulted in increased Cell therapies for therapeutic angiogenesis 157 left ventricular ejection fraction, collateral flow and capillary density. 72 In murine 73, 74 and rat 75,76 models of MI involving either autologous cells or human cells, respectively, mobilization or administration of EPCs resulted in increased left ventricular ejection fraction (LVEF) and capillary density, and decreased infarct size and cardiomyocyte apoptosis.
In models of hindlimb ischemia, EPCs were also implicated in increased capillary density, muscle perfusion and functional recovery and, in some studies, reported to contribute significantly (as much as 50%) to new vessel formation. 77, 78 However, the specific contribution of putative EPCs to neovascularization remains debated, with other studies suggesting that EPCs are not directly incorporated into the vessel wall, but are instead recruited to perivascular locations and promote neovascularization by the secretion of paracrine factors. 79, 80 Fundamentally, these discordant findings arise from the lack of uniform cellular definitions for EPCs, and the use heterogeneous, unselected cell populations making the comparison of many studies difficult.
Different angiogenic properties of putative EPCs
In a recent study conducted by Yoder et al., early EPCs and OECs were analyzed in a side-by-side comparison. 81 They reported that early EPCs are cells of low proliferative potential, which are hematopoietic in origin and differentiate into macrophages, capable of ingesting and killing microbes, rather than ECs in culture. In contrast, OECs could be distinguished by their lack of CD14 or CD45 and high proliferative potential being capable of generating secondary colonies from single cells.
Recently, we have also been able to show strikingly different angiogenic properties of these putative EPCs. In a study involving a novel co-culture assay, we demonstrated that early EPCs do not directly participate in, but augment vascular network formation in a paracrine fashion. In contrast, OECs formed tubules de novo and incorporated into developing vascular networks but exerted no paracrine angiogenic effects ( Table 2) . 82 Our data are consistent with the earlier findings of others who have shown that, in comparison to OECs, early EPCs produce higher levels of angiogenic peptides, prompting some to refer to early EPCs as circulating angiogenic cells or CACs. 79, 83 The notion that early EPCs secrete growth factors such as VEGF, hepatocyte growth factor (HGF), granulocyte colony-stimulating factor (G-CSF) and interleukin-8 (IL-8) reconciles the data accumulated from numerous studies showing limited incorporation of EPCs into newly formed vessels despite increased neovascularization. 80 Collectively, these findings sug-gest that OECs and not early EPCs are 'true' progenitors of endothelial cells. Indeed, Yoon et al. highlight that early EPCs and OECs may operate in a synergistic fashion by providing 'software' and 'hardware' for neovascularization respectively. 83 The different angiogenic properties of early EPCs and OECs suggest that these cells may have distinct therapeutic roles and that different strategies may be required to optimally harness their respective potential for therapeutic neovascularization.
Bone marrow cells (BMCs)
What is a BMC? The term BMC refers to cells isolated from the bone marrow that are either crude and unfractionated, or mononuclear cells derived from density centrifugation. BMCs comprise a heterogeneous cell population that contains a number of stem/progenitor cells and, in addition to the hematopoietic stem cell (HSC), has also been shown to house mesenchymal stem cells (MSCs), hemangioblasts and, as highlighted earlier, EPCs. 7 Transplantation of a single non-adherent cell expressing c-kit and murine stem cell antigen-1 (sca-1) with the absence of a lineage marker (i.e. lin-) has been shown to result in the reconstitution of the bone marrow, which in turn provided cells that were found to contribute to the endothelium. 84 Additionally, xenotransplantation of human CD34+ cells for hematopoietic reconstitution in mice, revealed neovasculature of human origin in the context of retinal injury. 85 The role of BMCs in vascular regeneration Numerous animal studies have demonstrated that transplantation of BMCs improves cardiac function in settings of acute MI and ischemia. Both autologous and allogeneic transplants have been attempted using whole bone marrow, and bone marrow-derived CD34+ cells, CD133+ cells, MSCs, and EPCs. 86 The ability of BMCs to be mobilized and home to sites of injury has been studied in experimental pre-clinical and clinical settings. Takahashi et al. demonstrated that the cytokine G-CSF could be used to elevate levels of BMCs and enhance neovascularization in the context of hindlimb ischemia. 34 Subsequently, Orlic et al. were able to show that G-CSF and stem cell factor (SCF) were able to augment cardiac regeneration in mice. 87 In light of these findings, and seeing an opportunity to circumvent invasive cellular therapies, a number of clinical trials were undertaken to assess the ability of these cytokines to increase levels of stem/progenitor cells in patients with coronary artery disease and acute myocardial infarction (AMI). 88, 89 Unfortunately, in the two largest placebo-controlled doubleblinded trials of G-CSF, no improvement in ventricular remodeling or infarct size compared to controls was detected. 90, 91 These findings suggest that stimulation of systemic stem/progenitor cell mobilization alone is insufficient to promote cardiovascular regeneration.
The mechanisms by which BMCs aid in vascular regeneration have been a source of controversy. Early work suggested the possibility that BMCs directly transdifferentiate from hematopoietic cells into myocardium. 74 Subsequent studies have been unable to confirm this and BMC transdifferentiation now seems unlikely. 86, 92 It is now appreciated that BMC transplantation likely preserves the ischemic myocardium via the secretion of pro-survival and pro-angiogenic paracrine factors. 92, 93 Ultimately, the contradictory findings generated by studies of whole bone marrow preparations for cell therapy reflect the fact that such approaches are 'blunderbuss' in nature. That is, BMCs represent a heterogeneous population of cells containing only a small percentage of ideal stem/progenitor cells. As suggested earlier, these studies prompt us to identify and understand the biology of specific bone marrow-derived progenitors that are relevant for neovascularization.
Mesenchymal stem cells (MSCs)
What is a MSC? A mesenchymal stem cell is a non-hematopoietic cell chiefly found in the bone marrow. These cells are multipotent, meaning they can differentiate into stromal cells that give rise to a variety of mesenchymal cells such as osteoblasts, chondrocytes, adipocytes, and even myoblasts. 94 Like EPCs, MSCs express a plurality of markers, none of which are specific to MSCs. It is generally agreed that adult human MSCs express markers including CD105, CD44, CD90 and Stro-1 as well as the adhesion molecules VCAM-1 and ICAM-1, but do not express the hematopoietic markers CD45, CD34, CD14, and CD11, or other costimulatory molecules. 95 Interestingly, MSCs lack the major histocompatibility complex II and appear to be non-immunogenic when transplanted from one individual to another. 72 MSCs are therefore unique in being potentially suitable for allogeneic cell transplantation without immunosuppression. This, combined with their proclivity to ex vivo expansion, makes them an attractive modality for therapy. 95 As such, the potential role of MSCs in cardiovascular regeneration has been intensely investigated. 96 To date, animal studies have revealed a variety of benefits associated with MSC treatment ranging from decreased myocardial scar and infarct size, improved ventricular function and increased vascular density of the myocardium. 97 The role MSCs in vascular regeneration It is increasingly appreciated that MSCs, like early EPCs, may mediate cardiovascular repair, via paracrine means. MSCs have been shown to secrete an array of different pro-angiogenic peptides including HGF, insulin-like growth factor-1 (IGF-1), basic fibroblast growth factor (bFGF), VEGF, and angiopoeitin-1 (Ang-1). 98 Additionally, although the mechanisms are not yet fully understood, it has been repeatedly demonstrated that MSCs have the ability to home to tissues particularly if they are ischemic or inflamed. 95 Taken together, MSCs represent an exciting cellular alternative, with some studies investigating the use of MSCs as vectors for gene therapy or pro-angiogenic growth factor delivery. 99 MSCs have been demonstrated to have the capacity to take on a cardiomyocytic phenotype in vitro. 100 Therefore, it was hypothesized that, in vivo, these cells would differentiate and effect regeneration by providing functional cardiomyocytes. 97 However, the evidence of differentiation in vivo has been only modest and suggests that their observed therapeutic effects were paracrinemediated. 96 Indeed, a recent side-by-side comparison of EPCs and MSCs demonstrated that increased capillary density in infarcted myocardium with halted progression of left ventricular dysfunction was mediated by EPCs and not MSCs. 101 Additionally, recent animal studies have called into question the long-term safety of MSC therapy for MI after some studies reported insufficient engraftment of MSCs and frequent calcifications at sites of injection. 102 However, ongoing Phase I/II clinical trials devoted to MSC therapy for MI, as well as chronic ischemic heart disease and ischemic cardiomyopathy, will continue to illuminate the safety and utility, and potential of this particular modality.
Adipose-derived stem cells (ADSCs)
Stem cells that are derived non-adipocyte fractions from adipose tissue (e.g. stromal vascular cells) have been investigated for potential use in cell therapies. 103, 104 These cells express both hematopoietic and endothelial markers, and have the capacity to differentiate into endothelial cells, and promote post-ischemic neovascularization in murine hindlimbs. The observed pro-angiogenic effects of these cells were demonstrated by their ability to secrete pro-angiogenic peptides to prevent EC apoptosis and incorporate into the murine vasculature. 103, 104 In a model of MI, intracoronary delivery of ADSCs improved cardiac function and perfusion via neovascularization. 105 Cardiac stem/progenitor cells (CSCs or CPCs) Multipotent cardiovascular stem and progenitor cells have been found in the fetal heart, which give rise to cardiomyocytes, smooth muscle cells and endothelial cells. 106, 107 Beltrami et al. were also able to identify a population of self-renewing multipotent cells from adult hearts, which could also differentiate into cardiomyocytes, smooth muscle cells and endothelial cells in vitro and in vivo. 108 Injection of these cells into the infarcted myocardium in mice has been associated with short-term benefit to cardiac function. 108, 109 In a recent study of MI using rats, CPCs were isolated and pre-activated with insulin-like growth factor 1 and hepatocyte growth factor prior to their injection. 110 This pre-activation enabled the CPCs to repair infarcted myocardium through the formation of regenerate conductive, intermediate-sized and small coronary arteries and arterioles together with capillary structures. This, in part, replaced the function of the occluded coronary artery and its distal branches and, in the short-term, attenuated post-infarction dilated myopathy, reduced infarct size and improved function. 110 In light of these findings, CPCs are an attractive candidate cell for therapeutic neovascularization as they have the ability to differentiate into vascular cells as well as cardiomyocytes, and the ability to form larger conductive arteries. However, it remains to be seen what the long-term outcomes of this cell therapy will be, and whether administration of these cells in larger animal models is safe and efficacious.
Embryonic stem cells (ESCs) and reprogrammed somatic cells
As mentioned above, embryonic stem cells (ESCs) have an increased capacity for self-renewal and the ability to differentiate into various functional cell types (Figure 1) . They have been isolated from mice, 111 and were isolated from humans only 10 years ago. 18 In light of their pluripotency and unlimited capacity for self-renewal, ESCs clearly represent an attractive candidate for cellular therapies, as theoretically they have the ability to replace entire organs.
In order to obviate ethical dilemmas in using fertilized human embryos, a number of methods have been described wherein a state of pluripotency has been induced. 17 Historically, this has involved the transfer of the nucleus of a somatic (or differentiated) cell into a denucleated oocyte; a process called somatic cell nuclear transfer (SCNT), which produces ESCs that are 'isogenic' for the donor of the somatic nucleus, thereby, theoretically, avoiding immunosuppression when used for subsequent therapy.
Recently, reprogramming of differentiated adult cells to a state of pluripotency has been achieved using both human and murine fibroblasts. 19, 20 In groundbreaking work, two groups independently transduced genes encoding four transcription factors found to be necessary in maintaining a pluripotent phenotype (comprising c-Myc, Klf4, Oct4 and Sox2 20 or Nanog, Lin 28, Oct4 and Sox2 19 ) into adult fibroblasts to produce induced pluripotent stem (iPS) cells with near identical functional and genetic properties compared to human ESCs. Recent reports indicate that inducible pluripotency can be enhanced by small molecules such as methylation inhibitors, and can be achieved with as few as two reprogramming factors depending on the cell types used. 112 The role of ESCs/iPS cells in vascular regeneration Pluripotent stem cells, such as ESCs and iPS cells, are promising sources of cells for cardiovascular regeneration as they are able to undergo differentiation into cardiomyocytes as well as vascular smooth muscle cells and endothelial cells. 5 Several studies assessing transplantation of cardiomyocytes and other non-cardiomyocytic cells derived from human ESCs in rodent models of MI have shown improved cardiac function, at least in the short term (< 12 weeks). 21, 113 Additional studies of ESCs differentiated to form endothelial cells and smooth muscle cells have shown the ability of these cells to integrate into the host circulation. 57, 114 Indeed, ESC-derived endothelial cells have been shown to enhance revascularization in models of hindlimb ischemia and MI. 115, 116 In a recent study tracking the fate of ESC-derived endothelial cells, survival of transplanted cells into infarcted murine myocardium was detected at 8 weeks post-infarct with functional improvement and increased vascular density. 116 Similarly, iPS cells have also recently been shown to differentiate into cells of the cardiovascular and hematopoietic lineages. 117 In a recent study by Rajasingh et al., 22 fibroblasts were reprogrammed, or de-differentiated, to pluripotency using cell extracts from ESCs (thereby circumventing the need for viral vectors) and subsequently re-differentiated into cells of various lineages. Importantly, transplantation of these reprogrammed cells, significantly enhanced neovascularization in murine models of hindlimb ischemia and MI, with evidence, albeit limited, of in vivo transdifferentiation into both endothelial cells and cardiomyocytes.
Limitations of ESC/iPS cell therapy
Somewhat ironically, owing to their pluripotency, ESCs or iPS cells that are transplanted in an undif-ferentiated form represent a safety concern because of their ability to form tumors and/or teratomas. Currently, differentiation of pluripotent cells to relevant cell types, followed by screening out undifferentiated cells prior to implantation appears to be the safest alternative to date. 118 However, successful translation from experimental and pre-clinical studies to clinical trials will require many technical challenges to be overcome. 118 Translational considerations: integrating cell biology with clinical application
Modes of delivery
The efficacy of cell therapies will depend on successful mobilization and homing of cells to the necessary sites and subsequent retention, before participation in neovascularization. This trafficking of cells will in part be determined by the mode of delivery. The alternatives available for the delivery of cells to the ischemic tissue include the intravascular route or direct intramuscular injection. For direct delivery of cells to the heart a number of delivery modalities have been assessed. These include: intracoronary arterial infusion, interstitial retrograde coronary venous delivery, transendocardial injection and transepicardial injection during surgery. 135 In a study comparing delivery of radio-labeled PBMNCs via the first three modes, intramyocardial injection was more efficient with less systemic 'spillover', but less consistent than the others. 119 Intracoronary infusion is preferable as it allows for the maximum dose of cells to be delivered. However, the threat of embolic complications arises when cells such as MSCs or ADSCs are used, as they are adherent cells, typically twice the diameter of microvessels, capable of forming aggregates and causing microinfarctions. 105, 120 These issues are circumvented when intramyocardial injection is employed, which also has the benefit of giving cells direct access to target tissue which may not have been otherwise accessible due to impaired perfusion. However, introduction of progenitor cells into necrotic tissue, which lacks both blood flow and paracrine support of surrounding cardiomyocytes, reduces cell survival and differentiation. 30 Another alternative for increasing the efficiency of cell retention could be a recently described novel, closed-loop percutaneous catheter-based recirculating cardiac perfusion system. 121 Briefly, this involves recapture of coronary venous blood from the coronary sinus via a percutaneously positioned occlusive balloon recovery catheter. Venous return is facilitated with a roller pump, followed by reoxygenation using an oxygenator membrane. Oxygenated perfus-ate is then directed to the coronary territory via a non-occlusive catheter placed percutaneously in the left main coronary artery. Previously used for gene delivery, this mechanism when applied to cells, could provide safe homogeneous myocardial delivery with limited retention of cells in undesired issues, such as the lungs, which is a problem with systemic administration. Ultimately, the optimal route will need to be determined by the characteristic of the cell(s) being administered, including their capacity for extravasation and migration.
Ex vivo modifications
It is now understood, that a plethora of influences such as disease states, aging and other traditional risk factors affect the functional activities of EPCs and BMCs. 122 These include, for example, their capacity for migration towards VEGF and SDF-1, colony formation, vascular network formation in vitro, and neovascularization in vivo. As such, identifying key strategies to mitigate these impairments will be important for successful translation of cell therapy. Such strategies may include making modifications to candidate cells ex vivo, such as pre-treatment or genetic correction, 123, 124 or administration in the presence of a pro-survival cocktail as described recently. 21 Among the first to attempt this approach were Mangi et al. who showed that MSCs overexpressing the anti-apoptotic gene Akt1 (Akt-MSCs) became more resistant to apoptosis in vitro and in vivo 125 and secreted paracrine factors that enhanced protection of the ischemic myocardium. 126 Alternatively, strategies may be directed towards pre-treating the site of desired localization to render it more receptive to candidate cells. 127 These strategies and others are reviewed elsewhere. 122 
Cell selection
The randomized trials of cell therapy including REPAIR-AMI, BOOST, and ASTAMI, 13, 15, 128 as well as the study by Janssens et al., 14 all evaluated the efficacy of intracoronary delivery of autologous BMCs following acute myocardial infarction, with mixed results. 129 Essentially, the BOOST and REPAIR-AMI trials showed short-term benefit to LV function; however, these findings were not replicated in the study by Janssens et al. or the ASTAMI trial, which showed no change to global contractility. Indeed, the long-term efficacy of these treatments was questioned in the 18-month followup of the BOOST trial, which revealed no difference in LV function between treated and control groups. 128 However, comparisons between these trials, and others, are confounded by differences in their design, the methods used for cell preparation and the time of delivery post-MI. For example, the REPAIR-AMI isolated cells using Ficoll ® density gradient buffer with subsequent overnight storage at room temperature in a buffer containing 20% serum, whereas the ASTAMI trial used Lymphoprep ® density gradient buffer for cell isolation and stored cells overnight at 4°C in NaCl containing 10% heparinplasma and 50 IU heparin. These differences have been purported to have profound influences on the cell phenotype and functionality. 130 Hence, the debate in the wake of these studies highlight the need for more thorough characterization of angiogenic cell populations, along with a need for clarification of cell isolation, processing and storage protocols.
Clearly, distinct therapeutic roles exist for different candidate cells. As outlined, some appear to principally promote neovascularization in a paracrine manner whilst other candidate cells materially contribute to the formation of vessels. It is likely, given the relatively low abundance of EPCs present, that the pro-angiogenic effects of heterogeneous BMC administration are mediated through paracrine factors. In this respect, more research is required to identify and characterize the pro-angiogenic factors secreted by these cells, along with cells possessing the most optimal expression profile of these factors. Indeed, the question remains open as to whether cells themselves, or just their secreted factors are required. In addition, with the growing understanding of immature cell populations resident in various tissues, particularly the heart, use of paracrine factors to activate these cells for regeneration in situ has broad applications. 131 As mentioned, candidate cells materially contribute to the formation of vessels, and may indeed provide the 'building blocks' for neovascularization. Furthermore, given that some candidates, such as OECs and MSCs, are particularly proliferative, they are potentially well suited for ex vivo expansion for subsequent therapeutic delivery. However, the delayed outgrowth of OECs in culture may limit their application in the context of recent ischemia if there proves to be a limited time window for clinical benefit. As such, optimization of cell isolation/ culture and timing of administration is required before these cells may be more appropriately investigated for clinical therapies.
Conclusion
Over the last decade, there has been a rapid translation of cellular therapies for therapeutic angiogenesis despite a limited understanding of the biology of candidate stem/progenitor cells. The mixed results and limited success of early clinical studies indicate that further pre-clinical evaluation and optimization is necessary before cell therapies for angiogenesis become mainstream treatments. As part of this 'back to bench' process, a number of key biological issues need to be addressed.
First, further elucidation of the precise mechanisms of neovascularization is required, particularly the role of various stem/progenitor cells in new vessel formation. Recently, data demonstrate that distinct putative EPCs have very different roles in angiogenesis, with important implications regarding how they (and/or their secreted factors) may be best harnessed as clinical therapies. Second, mobilization and/or homing to the target tissue are necessary for endogenous or administered cells, respectively. Increasing knowledge of these mechanisms, and their impairment by various disease processes, has led to the discovery of promising new strategies for tissue regeneration, such as treatment of target tissues with factors to promote progenitor homing and survival in ischemic tissue. Indeed, elucidation of these processes may lead us to resolve the current paradox that stem/progenitor cells exist in the heart (and other adult tissues), yet are unable to effect sufficient regeneration after injury. Third, while many candidate cells present themselves as attractive therapeutic options, robust in vitro and in vivo investigation of the biology of these cells is needed to identify those that are the most amenable to therapeutic modulation of angiogenesis. Specifically, future attention should focus on the differentiation capacity of each cell and the phenotype/function that is adopted following mobilization or administration. Indeed, increasing insight into the biology of cell differentiation and factors governing pluripotency has enabled new sources and strategies for generating pluripotent cells, capable of cardiovascular regeneration. Finally, other translational aspects such as how and when to effectively deliver the most appropriate number of cells to the target tissue, how to improve the retention of cells at the target tissue and how to improve their survival will need to be addressed in light of increasing appreciation of the biology of different candidate cells.
With ongoing efforts to translate cellular therapies, dynamic relationships between basic scientists, translational investigators and clinical trialists must be strengthened so that there is a critical evaluation of all steps from bench-to-bedside. Ultimately, successful integration of vascular biological insights into clinical strategy will enhance the probability that the early promise of cell therapies for angiogenesis will mature from hype to clinical reality.
